The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials

Dennis, Michael L.; Godley, Susan H.; Diamond, Guy; Tims, Frank M.; Babor, Thomas F.; Donaldson, Jean; Liddle, Howard A.; Titus, Janet C.; Kaminer, Yifrah; Webb, Charles; Hamilton, Nancy; Funk, Rodney R.

doi:10.1016/j.jsat.2003.09.005

Cited by 692 publications

(734 citation statements)

References 62 publications

Supporting

Mentioning

697

Contrasting

Unclassified

Order By: Relevance

“…13 Other studies also demonstrate the efficacy of MI/CBT as a treatment for adolescent SUD. 1,14 The MI/CBT consisted of hour-long, weekly individual sessions and could include up to three family sessions. Cognitive, behavioral, and motivational techniques were used to help adolescents reduce their drug use and improve coping.…”

Section: Methodsmentioning

confidence: 99%

Randomized, Controlled Trial of Atomoxetine for Attention-Deficit/Hyperactivity Disorder in Adolescents With Substance Use Disorder

Thurstone

Riggs

Salomonsen‐Sautel

et al. 2010

Journal of the American Academy of Child & Adolescent Psych

View full text Add to dashboard Cite

Objective-To evaluate the effect of atomoxetine hydrochloride versus placebo on attentiondeficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) in adolescents receiving motivational interviewing / cognitive behavioral therapy (MI/CBT) for SUD.Method-This single-site, randomized, controlled trial was conducted between December 2005 and February 2008. Seventy adolescents (13-19 years) with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) ADHD, a DSM-IV ADHD checklist score greater than or equal to 22, and at least one non-tobacco SUD were recruited from the community. All subjects received 12 weeks of atomoxetine hydrochloride + MI/CBT versus placebo + MI/CBT. The main outcome measure for ADHD was self-report DSM-IV ADHD checklist score. For SUD, the main outcome was self-report number of days used non-tobacco substances in the past 28 days using the Timeline Followback interview.Results-Change in ADHD scores did not differ between atomoxetine + MI/CBT and placebo + MI/CBT (F4,191 = 1.23, p = 0.2975). Change in days used non-nicotine substances in the last 28 days did not differ between groups (F3,100 = 2.06, p = 0.1103).Conclusions-There was no significant difference between the atomoxetine + MI/CBT and placebo + MI/CBT groups in ADHD or substance use change. The MI/CBT and/or a placebo effect may have contributed to a large treatment response in the placebo group.

show abstract

Section: Methodsmentioning

confidence: 99%

Randomized, Controlled Trial of Atomoxetine for Attention-Deficit/Hyperactivity Disorder in Adolescents With Substance Use Disorder

Thurstone

Riggs

Salomonsen‐Sautel

et al. 2010

Journal of the American Academy of Child & Adolescent Psych

View full text Add to dashboard Cite

show abstract

“…The therapist with the highest overall patient-rated alliance was used as the reference point. While we know that outcomes do not vary significantly based on treatment modality or site and that, as a whole, the CYT sample significantly improved, 20 this strategy allows us to control for these nested effects within each therapist. Block 4 (Patient-Therapist Match): Previously, we found patient-therapist sex and racial match to predict treatment retention; 30 therefore, we included these variables as possible covariates.…”

Section: Analysis Planmentioning

confidence: 99%

Early Therapeutic Alliance as a Predictor of Treatment Outcome for Adolescent Cannabis Users in Outpatient Treatment

et al. 2006

Self Cite

View full text Add to dashboard Cite

The association of early alliance to treatment attendance and longitudinal outcomes were examined in 356 adolescents participating in a randomized clinical trial targeting cannabis use. Both patient and therapist views of alliance were examined, and outcomes were evaluated over 12 months after numerous other sources of variance were controlled. Patient-rated alliance predicted a reduction in cannabis use at three and six months and a reduction in substancerelated problem behaviors at six months. Therapistrated alliance did not predict outcomes. Neither patient nor therapist alliance ratings were associated with attendance. The findings support the important and often overlooked role that alliance can play in treating substance abusing, often delinquent, adolescents. (Am J Addict 2006;15:26-33)

show abstract

“…Five published studies were identified: Matching Alcohol Treatment to Client Heterogeneity, (MATCH) ( Project MATCH Research Group, 1997;Project MATCH Research Group, 1993); The Cannabis Youth Treatment Study (Cannabis Youth) (Dennis et al, 2004;Dennis et al, 2002); NIDA Collaborative Cocaine Treatment Study (Cocaine Collaborative) (Crits-Christoph et al, 1997;Crits-Christoph et al, 1999); Project COMBINE (COMBINE) (COMBINE Study Research Group, 2003); and the United Kingdom Alcohol Treatment Trial, (UKATT) (Team., 2005;UKATT Research Team, 2001). Additionally, we reviewed seven multi-site studies conducted within the NIDA CTN: Motivational Interviewing/Motivational Enhancement Therapy (MI/MET) (Carroll et al, 2006); HIV Risk Reduction During Detoxification (HIV-Detox) (Booth, 2005); Concurrent Treatment for Women with Trauma (Women and Trauma) (Hein, 2006); Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs (Smoking Cessation) (Reid, 2004); Job Seeker Training (Job Seekers) (Svikis, 2003); Safer Sex Skills for Women and Men (Safe Sex Skills) (Tross, 2005), (Calsyn, 2004); Brief Strategic Family Therapy (BSFT) (Szapocznik, 2004).…”

Section: Methodsmentioning

confidence: 99%

Training and fidelity monitoring of behavioral interventions in multi-site addictions research

Baer

Ball

Campbell

et al. 2007

Drug and Alcohol Dependence

105

View full text Add to dashboard Cite

AIMS-Methods for the training and fidelity monitoring of behavioral interventions in multi-site addictions research are reviewed, including five published studies and seven ongoing studies sponsored by the National Institute on Drug Abuse-funded Clinical Trials Network.METHODS-Methods are categorized and reviewed consistent with a technology model of treatment delivery. Topics include: therapist selection, training, certification, and supervision; selection, training, and certification of supervisors; scales and processes used for monitoring of the quality of treatment; and processes followed to provide new training for replacement staff once trials have begun. RESULTS-The review reveals both a wide array of procedures and emerging standards for multisite trials. Methodological weakness was observed with respect to limited empirical support for many adherence scales, little or no evaluation of supervisory processes, and no evaluation of retraining practices.CONCLUSIONS-Methods used in multi-site trials are important not only to ensure validity of those trials, but also to inform the wider dissemination of empirically based treatment into community agencies. Studies examining noted weaknesses are needed. Training and fidelity models that delegate responsibility to participating sites appear most relevant for establishing best practices for dissemination of behavioral interventions. The effectiveness of these distributed training and

show abstract

The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials

Cited by 692 publications

References 62 publications

Randomized, Controlled Trial of Atomoxetine for Attention-Deficit/Hyperactivity Disorder in Adolescents With Substance Use Disorder

Randomized, Controlled Trial of Atomoxetine for Attention-Deficit/Hyperactivity Disorder in Adolescents With Substance Use Disorder

Early Therapeutic Alliance as a Predictor of Treatment Outcome for Adolescent Cannabis Users in Outpatient Treatment

Training and fidelity monitoring of behavioral interventions in multi-site addictions research

Contact Info

Product

Resources

About